Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Cancer
|
February 1, 1992
Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer
I B Vergote, L N Vergote-De Vos, V M Abeler, et al.
Gynecologic Oncology
|
January 31, 2006
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study
H Hirte, I B Vergote, J R Jeffrey, et al.
British Journal of Cancer
|
September 1, 1986
Prostacyclin and thromboxane in benign and malignant breast tumours
G M Laekeman, I B Vergote, G M Keersmaekers, et al.
Journal of Clinical Pathology
|
October 1, 1994
Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma
P A van Dam, I B Vergote, D G Lowe, et al.
British Journal of Cancer
|
June 1, 1985
Prostaglandin F2 alpha in benign and malignant breast tumours
I B Vergote, G M Laekeman, G H Keersmaekers, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 7, 2006
Predicting the clinical behavior of ovarian cancer from gene expression profiles
F De Smet, N L M M Pochet, K Engelen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2013
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
F A Raja, N Counsell, N Colombo, et al.
Gynecologic Oncology
|
December 12, 2019
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies
I B Vergote, B Lund, U Peen, et al.
Facts, Views & Vision in Obgyn
|
December 12, 2019
The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG)
Waa Tjalma, Jja Bosteels, I Cooremans, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Cancer
|
February 1, 1992
Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer
I B Vergote, L N Vergote-De Vos, V M Abeler, et al.
Gynecologic Oncology
|
January 31, 2006
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study
H Hirte, I B Vergote, J R Jeffrey, et al.
British Journal of Cancer
|
September 1, 1986
Prostacyclin and thromboxane in benign and malignant breast tumours
G M Laekeman, I B Vergote, G M Keersmaekers, et al.
Journal of Clinical Pathology
|
October 1, 1994
Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma
P A van Dam, I B Vergote, D G Lowe, et al.
British Journal of Cancer
|
June 1, 1985
Prostaglandin F2 alpha in benign and malignant breast tumours
I B Vergote, G M Laekeman, G H Keersmaekers, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 7, 2006
Predicting the clinical behavior of ovarian cancer from gene expression profiles
F De Smet, N L M M Pochet, K Engelen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 6, 2013
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
F A Raja, N Counsell, N Colombo, et al.
Gynecologic Oncology
|
December 12, 2019
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies
I B Vergote, B Lund, U Peen, et al.
Facts, Views & Vision in Obgyn
|
December 12, 2019
The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG)
Waa Tjalma, Jja Bosteels, I Cooremans, et al.
Page
of 4